[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639685":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":25,"id":54,"slug":25,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":57,"conditions":70,"keywords":25,"overallStatus":73,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A (RT)","EXPERIMENTAL","Period 1: Reference Drug(AD-231A, AD-231D and AD-231C), Period 2 : Test Drug(AD-231)",[13,14],"Drug: AD-231","Drug: AD-231A, AD-231D and AD-231C",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B (TR)","Period 1: Test Drug(AD-231), Period 2 : Reference Drug(AD-231A, AD-231D and AD-231C)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-231","AD-231 Oral Tablet",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-231A, AD-231D and AD-231C","AD-231A Oral Tablet + AD-231D Oral Tablet + AD-231C Oral Tablet",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Dasom KIM","CONTACT","+82-31-891-5572","dskim@addpharma.co.kr",[37],{"facility":38,"status":25,"city":39,"state":25,"zip":25,"country":40,"countryCode":25,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"H Plus Yangji Hospita","Seoul","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.9784,37.566,{"lat":45,"lon":44},[48],{"name":49,"role":33,"phone":50,"phoneExt":25,"email":51},"Moonjung Bae","+82-70-4665-9174","m4222@newyjh.com",{"type":53,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100639685",false,"NCT07590167","A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE1",[71,72],"Dyslipidemia","Hypertension","NOT_YET_RECRUITING","2026-05-11",{"date":76,"type":77},"2026-05-15","ACTUAL",{"date":79,"type":66},"2026-06",{"date":81,"type":66},"2026-07",{"name":5,"class":6},1]